Dong-A Socio Holdings subsidiary BTGen signed a ₩13.66 billion contract to manufacture pharmaceuticals for an unnamed global drug company. The value equals 13.2% of BTGen's 2025 separate-basis revenue. The customer will pay a ₩1.05 billion advance and make further payments as requested work is completed. The contract runs through June 30, 2027, but the end date may change by agreement.